HRP20221355T1 - Liofilizirani pripravak citotoksičnih dipeptida - Google Patents
Liofilizirani pripravak citotoksičnih dipeptida Download PDFInfo
- Publication number
- HRP20221355T1 HRP20221355T1 HRP20221355TT HRP20221355T HRP20221355T1 HR P20221355 T1 HRP20221355 T1 HR P20221355T1 HR P20221355T T HRP20221355T T HR P20221355TT HR P20221355 T HRP20221355 T HR P20221355T HR P20221355 T1 HRP20221355 T1 HR P20221355T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- pharmaceutical preparation
- melphalan flufenamide
- lyophilized pharmaceutical
- solution
- Prior art date
Links
- 108010016626 Dipeptides Proteins 0.000 title 1
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 230000001472 cytotoxic effect Effects 0.000 title 1
- YQZNKYXGZSVEHI-VXKWHMMOSA-N ethyl (2s)-2-[[(2s)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate Chemical compound C([C@@H](C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(=CC=1)N(CCCl)CCCl)C1=CC=C(F)C=C1 YQZNKYXGZSVEHI-VXKWHMMOSA-N 0.000 claims 10
- 229950009924 melphalan flufenamide Drugs 0.000 claims 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 239000000243 solution Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 4
- 239000003960 organic solvent Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 235000019441 ethanol Nutrition 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims 1
- 235000011054 acetic acid Nutrition 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A61K38/105—Bombesin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (12)
1. Liofilizirani farmaceutski pripravak, naznačen time, da sadržava:
(i) melfalan flufenamid, ili njegovu farmaceutski prihvatljivu sol; i
(ii) saharozu.
2. Liofilizirani farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time, da je količina pomoćne tvari od 10 do 100 % težinskog udjela navedenog melfalan flufenamida.
3. Liofilizirani farmaceutski pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time, što nadalje sadržava fiziološki prihvatljivu otopinu.
4. Liofilizirani farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time, što je nema ili je znatno oslobođen od organskih otapala.
5. Pribor, naznačen time, da se sastoji od
(i) liofiliziranog farmaceutskog pripravka sukladno bilo kojem od patentnih zahtjeva 1-4; i
(ii) fiziološki prihvatljive otopine.
6. Liofilizirani farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time, da se koristi kao lijek.
7. Liofilizirani farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time, da se koristi u liječenju i/ili prevenciji raka.
8. Liofilizirani farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačen time, što je rečeni rak bilo koji od raka jajnika, raka pluća, raka mokraćnog mjehura, mezotelioma, višestrukog mijeloma, raka dojke ili hematoloških oblika raka.
9. Komplet dijelova u skladu s patentnim zahtjevom 5, naznačeno time, da je za upotrebu u liječenju raka, na primjer gdje je navedeni rak bilo koji od raka jajnika, raka pluća, raka mokraćnog mjehura, mezotelioma, višestrukog mijeloma, raka dojke ili hematoloških oblika raka.
10. Postupak priprave liofiliziranog farmaceutskog pripravka u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time, da:
a. melfalan flufenamid ili njegova farmaceutski prihvatljiva sol je rastopljen u organskom otapalu kako bi se dobila otopina melfalan flufenamida;
b. voda se dodaje u otopinu melfalan flufenamida kako bi se dobila vodena otopina melfalan flufenamida, u koncentraciji od 0,2-3,0 mg / ml;
c. saharoza se dodaje otopini melfalan flufenamida; i
d. vodena otopina melfalan flufenamida koja sadrži pomoćnu tvar/tvari podvrgava se liofilizaciji.
11. Postupak u skladu s patentnim zahtjevom 10, naznačen time, da:
a. melfalan flufenamid ili njegova farmaceutski prihvatljiva sol je rastopljena u organskom otapalu;
b. voda se dodaje otopini dobivenoj u koraku a) kako bi se dobila otopina rečenog melfalan flufenamida ili njegova farmaceutski prihvatljiva sol, u koncentraciji od 0,2-3,0 mg / ml;
c. saharoza se dodaje otopini dobivenoj u koraku b); i
d. otopina dobivena u koraku c) podvrgava se liofilizaciji.
12. Postupak u skladu s patentnim zahtjevom 10 ili 11, naznačeno time, što je organsko otapalo odabrano između bilo kojeg od etanola, kiseline koja sadrži etanol, glicerina, propilen glikola, benzil alkohola, dimetilacetamida (DMA), N-metil-2- pirolidona, izopropanola, n-butanola, terc-butanola, metil terc-butil etera, propilen glikola, dimetilsulfoksida, tetrahidrofurana, 2-metil tetrahidrofurana, acetona, dimetilformamida, acetonitrila, dioksana, octene kiseline, mliječne kiseline, propionske kiseline, n-butanola, izopropanola, n-propanola, terc-butanola, sek-butanola, metanola i smjese etanola i vode.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1150371 | 2011-04-28 | ||
US201161535126P | 2011-09-15 | 2011-09-15 | |
EP19215699.0A EP3656393B1 (en) | 2011-04-28 | 2012-04-25 | Lyophilized preparation of cytotoxic dipeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20221355T1 true HRP20221355T1 (hr) | 2022-12-23 |
Family
ID=47071620
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20221355TT HRP20221355T1 (hr) | 2011-04-28 | 2012-04-25 | Liofilizirani pripravak citotoksičnih dipeptida |
HRP20171523TT HRP20171523T1 (hr) | 2011-04-28 | 2017-10-10 | Liofilizirani pripravak citotoksičnih dipeptida |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171523TT HRP20171523T1 (hr) | 2011-04-28 | 2017-10-10 | Liofilizirani pripravak citotoksičnih dipeptida |
Country Status (27)
Country | Link |
---|---|
US (7) | US20140128462A1 (hr) |
EP (4) | EP3656393B1 (hr) |
JP (1) | JP6042412B2 (hr) |
KR (2) | KR102122416B1 (hr) |
CN (2) | CN103547279A (hr) |
AU (1) | AU2012247545B2 (hr) |
BR (2) | BR122019017088B1 (hr) |
CA (2) | CA3024230C (hr) |
CY (2) | CY1119453T1 (hr) |
DK (3) | DK3656393T3 (hr) |
ES (2) | ES2642676T3 (hr) |
FI (1) | FIC20230004I1 (hr) |
FR (1) | FR23C1000I2 (hr) |
HR (2) | HRP20221355T1 (hr) |
HU (3) | HUE037863T2 (hr) |
IL (3) | IL228889A0 (hr) |
LT (2) | LT3656393T (hr) |
MX (1) | MX345102B (hr) |
NL (1) | NL301206I2 (hr) |
NO (1) | NO2023004I1 (hr) |
PL (3) | PL3656393T3 (hr) |
PT (2) | PT3656393T (hr) |
RS (3) | RS60719B1 (hr) |
RU (1) | RU2597154C2 (hr) |
SI (2) | SI2701720T1 (hr) |
WO (1) | WO2012146625A1 (hr) |
ZA (1) | ZA201308765B (hr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3656393T (pt) | 2011-04-28 | 2022-11-03 | Oncopeptides Ab | Preparação liofilizada de dipéptidos citotóxicos |
JP5827178B2 (ja) * | 2012-06-05 | 2015-12-02 | 北越紀州製紙株式会社 | セルロース多孔質体及びその製造方法 |
ES2768268T3 (es) * | 2012-10-26 | 2020-06-22 | Oncopeptides Ab | Preparaciones liofilizadas de melfalán flufenamida |
CA2889753C (en) | 2012-10-26 | 2021-03-02 | Oncopeptides Ab | Lyophilized preparations of melphalan flufenamide |
GB201507903D0 (en) | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
GB201521217D0 (en) * | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
US10369077B2 (en) * | 2017-05-31 | 2019-08-06 | Adienne Pharma & Biotech Sa | Multi chamber flexible bag and methods of using the same |
SG11202103726RA (en) * | 2018-10-18 | 2021-05-28 | Oncopeptides Ab | Compounds containing deuterium |
CN114025753A (zh) | 2019-04-03 | 2022-02-08 | 肿瘤多肽有限公司 | 用美氟芬治疗al淀粉样变性 |
GB201905477D0 (en) * | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
WO2021053185A1 (en) | 2019-09-20 | 2021-03-25 | Oncopeptides Ab | Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma |
EP4145995A4 (en) * | 2020-05-08 | 2024-05-22 | Cjb Applied Tech Llc | PESTICIDE COMPOSITIONS AND RELATED METHODS |
GB202109894D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
WO2023281007A1 (en) | 2021-07-08 | 2023-01-12 | Oncopeptides Ab | Melflufen for use in the treatment of multiple myeloma |
GB202109895D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
GB202109896D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
GB202204171D0 (en) | 2022-03-24 | 2022-05-11 | Oncopeptides Ab | Novel formulations |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB750155A (en) | 1953-03-17 | 1956-06-13 | Nat Res Dev | Substituted alanines |
GB8727157D0 (en) * | 1987-11-19 | 1987-12-23 | Wellcome Found | Pharmaceutical formulations |
JP3176716B2 (ja) | 1991-06-21 | 2001-06-18 | 武田薬品工業株式会社 | 溶解性が向上した難水溶性薬物組成物 |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US6992207B2 (en) * | 2000-06-13 | 2006-01-31 | Oncopeptides Ab | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
SE0002202D0 (sv) * | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
CA2464250C (en) | 2001-10-24 | 2008-08-05 | Frank-Christophe Lintz | Kit for the preparation of a pharmaceutical composition |
PL205936B1 (pl) * | 2002-02-22 | 2010-06-30 | Schering Corp | Farmaceutyczny preparat zawierający termozolomid oraz sposób jego wytwarzania |
US6780324B2 (en) * | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US20040034099A1 (en) * | 2002-06-27 | 2004-02-19 | Ramsey Beverly J. | Pharmaceutical composition |
US20050152979A1 (en) * | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
CN101039660B (zh) | 2004-08-12 | 2010-10-06 | 先灵公司 | 稳定的聚乙二醇化干扰素制剂 |
RU2382647C2 (ru) * | 2004-10-29 | 2010-02-27 | Фарма Мар С.А., Сосьедад Униперсональ | Композиции, содержащие эктинэсайдин и дисахарид |
EP1674098A1 (en) * | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
PL2038275T3 (pl) | 2006-07-07 | 2010-08-31 | Gilead Sciences Inc | Nowe pochodne pirydazyny i ich zastosowanie |
ES2665917T3 (es) | 2006-11-21 | 2018-04-30 | Jina Pharmaceuticals Inc. | Endoxifeno para su uso en el tratamiento del cáncer |
CN101584669B (zh) * | 2009-06-19 | 2010-12-29 | 江苏奥赛康药业有限公司 | 美法仑冻干粉针剂 |
WO2011078782A1 (en) * | 2009-12-22 | 2011-06-30 | Oncopeptides Ab | A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer |
AR077384A1 (es) | 2010-07-05 | 2011-08-24 | Eriochem Sa | Una formulacion farmaceutica inyectable de melfalano. |
JP6161593B2 (ja) * | 2011-04-15 | 2017-07-12 | ヤンセン ファーマシューティカ エヌ.ベー. | 凍結乾燥された薬物ナノ懸濁物 |
PT3656393T (pt) | 2011-04-28 | 2022-11-03 | Oncopeptides Ab | Preparação liofilizada de dipéptidos citotóxicos |
CA2889753C (en) | 2012-10-26 | 2021-03-02 | Oncopeptides Ab | Lyophilized preparations of melphalan flufenamide |
-
2012
- 2012-04-25 PT PT192156990T patent/PT3656393T/pt unknown
- 2012-04-25 PL PL19215699.0T patent/PL3656393T3/pl unknown
- 2012-04-25 LT LTEP19215699.0T patent/LT3656393T/lt unknown
- 2012-04-25 HR HRP20221355TT patent/HRP20221355T1/hr unknown
- 2012-04-25 EP EP19215699.0A patent/EP3656393B1/en active Active
- 2012-04-25 BR BR122019017088-6A patent/BR122019017088B1/pt active IP Right Grant
- 2012-04-25 HU HUE12718949A patent/HUE037863T2/hu unknown
- 2012-04-25 KR KR1020177035122A patent/KR102122416B1/ko active IP Right Grant
- 2012-04-25 CA CA3024230A patent/CA3024230C/en active Active
- 2012-04-25 RS RS20201030A patent/RS60719B1/sr unknown
- 2012-04-25 HU HUE19215699A patent/HUE060783T2/hu unknown
- 2012-04-25 CN CN201280019920.7A patent/CN103547279A/zh active Pending
- 2012-04-25 ES ES12718949.6T patent/ES2642676T3/es active Active
- 2012-04-25 SI SI201231086T patent/SI2701720T1/sl unknown
- 2012-04-25 ES ES19215699T patent/ES2930140T3/es active Active
- 2012-04-25 US US14/113,768 patent/US20140128462A1/en not_active Abandoned
- 2012-04-25 SI SI201231829T patent/SI3228319T1/sl unknown
- 2012-04-25 BR BR112013027584-7A patent/BR112013027584B1/pt active IP Right Grant
- 2012-04-25 RU RU2013152751/15A patent/RU2597154C2/ru active
- 2012-04-25 DK DK19215699.0T patent/DK3656393T3/da active
- 2012-04-25 DK DK12718949.6T patent/DK2701720T3/en active
- 2012-04-25 EP EP12718949.6A patent/EP2701720B1/en active Active
- 2012-04-25 MX MX2013012545A patent/MX345102B/es active IP Right Grant
- 2012-04-25 PL PL17173249T patent/PL3228319T3/pl unknown
- 2012-04-25 AU AU2012247545A patent/AU2012247545B2/en active Active
- 2012-04-25 JP JP2014506850A patent/JP6042412B2/ja active Active
- 2012-04-25 KR KR1020137031096A patent/KR101808895B1/ko active IP Right Grant
- 2012-04-25 LT LTEP12718949.6T patent/LT2701720T/lt unknown
- 2012-04-25 EP EP22191185.2A patent/EP4122482A1/en active Pending
- 2012-04-25 EP EP17173249.8A patent/EP3228319B1/en active Active
- 2012-04-25 CN CN201810054866.9A patent/CN108096563A/zh active Pending
- 2012-04-25 PL PL12718949T patent/PL2701720T3/pl unknown
- 2012-04-25 RS RS20221059A patent/RS63747B1/sr unknown
- 2012-04-25 RS RS20171002A patent/RS56462B1/sr unknown
- 2012-04-25 CA CA2833500A patent/CA2833500C/en active Active
- 2012-04-25 WO PCT/EP2012/057577 patent/WO2012146625A1/en active Application Filing
- 2012-04-25 PT PT127189496T patent/PT2701720T/pt unknown
- 2012-04-25 DK DK17173249.8T patent/DK3228319T3/da active
-
2013
- 2013-10-15 IL IL228889A patent/IL228889A0/en active IP Right Grant
- 2013-11-21 ZA ZA2013/08765A patent/ZA201308765B/en unknown
-
2016
- 2016-08-01 US US15/225,323 patent/US10322182B2/en active Active
-
2017
- 2017-10-10 HR HRP20171523TT patent/HRP20171523T1/hr unknown
- 2017-10-12 CY CY20171101070T patent/CY1119453T1/el unknown
-
2019
- 2019-03-19 IL IL265457A patent/IL265457B/en active IP Right Grant
- 2019-04-12 US US16/382,276 patent/US10543274B2/en active Active
- 2019-06-28 US US16/457,102 patent/US20200009252A1/en not_active Abandoned
- 2019-12-19 US US16/721,639 patent/US10869928B2/en active Active
-
2020
- 2020-02-03 IL IL272429A patent/IL272429B/en unknown
- 2020-07-22 US US16/935,372 patent/US11344622B2/en active Active
- 2020-08-12 CY CY20201100749T patent/CY1123242T1/el unknown
-
2022
- 2022-04-27 US US17/730,398 patent/US11896668B2/en active Active
- 2022-12-13 NL NL301206C patent/NL301206I2/nl unknown
-
2023
- 2023-01-04 FR FR23C1000C patent/FR23C1000I2/fr active Active
- 2023-01-16 HU HUS2300005C patent/HUS2300005I1/hu unknown
- 2023-01-16 NO NO2023004C patent/NO2023004I1/no unknown
- 2023-01-19 FI FIC20230004C patent/FIC20230004I1/fi unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20221355T1 (hr) | Liofilizirani pripravak citotoksičnih dipeptida | |
HRP20200567T1 (hr) | Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon | |
HRP20201300T1 (hr) | Liofilizirani pripravak citotoksičnih dipeptida | |
JP2014512402A5 (hr) | ||
JP2015535243A5 (hr) | ||
RU2015118581A (ru) | Лиофилизированные препараты мелфалана флуфенамида | |
EA201391758A1 (ru) | Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты | |
EP3556769B1 (en) | Polymyxin derivative, preparation method and application thereof | |
BR112015011179A8 (pt) | composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação | |
JP2013537212A5 (hr) | ||
RU2013108256A (ru) | Дисперсии цитрата разагилина | |
JP2014525449A5 (hr) | ||
MX2012001953A (es) | Composiciones fotosensibilizantes. | |
RU2020111026A (ru) | Препараты даптомицина | |
EA201600118A1 (ru) | Жидкая водная фармацевтическая композиция с консервантами, содержащая этерифицированные производные циклодекстрина | |
HRP20200387T1 (hr) | Tekući farmaceutski pripravak koji sadrži pemetreksed | |
RU2016106124A (ru) | Соли дасатиниба в аморфной форме | |
HRP20171181T1 (hr) | Pripravak smole koji se može razblažiti u vodi | |
WO2010045281A3 (en) | Stable aqueous formulations of water insoluble or poorly soluble drugs | |
JP2014515747A5 (hr) | ||
EA201590591A1 (ru) | Способ приготовления геля на основе полифенолов гранатовой кожуры для лечения воспалительных заболеваний в гинекологии | |
RU2016106125A (ru) | Соли дасатиниба в кристаллической форме | |
UA124818C2 (uk) | Композиція для ін'єкції | |
EA201270653A1 (ru) | Антагонист dpи его применение | |
RU2019119405A (ru) | Лиофилизированные фармацевтические композиции далбаванцина |